Arrowhead Pharmaceuticals. has filed a patent for RNAi agents targeting the SOD1 gene to treat diseases like ALS. The agents inhibit gene expression, offering therapeutic benefits. The claim specifies the nucleotide sequences for the RNAi agent. GlobalData’s report on Arrowhead Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Arrowhead Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arrowhead Pharmaceuticals, Targeted cancer therapy was a key innovation area identified from patents. Arrowhead Pharmaceuticals's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20240026363A1) discloses an RNAi agent designed to inhibit the expression of the Superoxide Dismutase 1 (SOD1) gene. The agent consists of an antisense strand and a sense strand, each comprising specific nucleotide sequences with modified bases and linkages. The length of the strands can vary between 18 and 30 nucleotides, with options for terminal caps, inverted abasic residues, and phosphorothioate linkages. Additionally, the RNAi agent can be conjugated to a lipid moiety for enhanced delivery and efficacy.

Furthermore, the patent describes a pharmaceutical composition containing the RNAi agent along with a pharmaceutically acceptable excipient, suitable for treating diseases associated with elevated mutant SOD1 activity levels. The method outlined involves introducing the RNAi agent into cells, particularly in human subjects, to inhibit SOD1 gene expression by at least 30%. This approach aims to address neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) or Alzheimer's Disease, with specific focus on SOD1-linked familial ALS. The dosage of the RNAi agent can range from 0.01 mg/kg to 5.0 mg/kg of body weight, offering a flexible and potentially effective treatment option for these conditions.

To know more about GlobalData’s detailed insights on Arrowhead Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies